Special Issue "New Therapies for Hepatocellular Carcinoma"
Deadline for manuscript submissions: closed (30 October 2020) | Viewed by 19441
Interests: hepatocellular carcinoma; cholangiocellular carcinoma; liver cancer; autoimmune hepatitis; celiac disease
Special Issues, Collections and Topics in MDPI journals
2. Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Interests: hepatocellular carcinoma; liver cancer; autoimmune hepatitis; primary biliary cholangitis; primary sclerosing cholangitis; celiac disease
The last few years have brought tremendous progress in the therapy of hepatocellular carcinoma, with immune oncology drugs (IOs) becoming pivotal players. Their success is not limited to the atezolizumab plus bevacizumab combination, as favorable results are coming from Phase 2 trials of dual immune checkpoint blockade and combination of IOs plus oral tirosine kinase inhibitors.
While this news is widely appreciated, new questions appear at the horizon. With no head-to-head trials, which frontline combination will be the most effective? Will we ever benefit from biomarkers to guide our choices? Which sequential treatments will grant the maximum benefit? What will be the role of tyrosine kinase inhibitors?
Additionally, the possible success of these combinations in the adjuvant and neo-adjuvant setting might revolutionize the whole therapeutic algorithm of hepatocellular carcinoma.
Finally, in a time in which the COVID-19 pandemic is putting a strain on most National Health Systems, cost-effectiveness data of these new combinations are urgently needed.
Therefore, we invite researchers to submit up-to-date original research articles, short communications, and review articles in this Special Issue of Pharmaceuticals.
Dr. Francesco Tovoli
Dr. Alessandro Granito
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatocellular carcinoma
- Malignant Glioma: Novel Therapeutic Strategies in Pharmaceuticals (7 articles)
- Cancer Translational Biomarkers and Targeted Therapies in Pharmaceuticals (16 articles)
- Clinical Development of Cancer Treatment in Pharmaceuticals (5 articles)
- Anticancer Drugs in Pharmaceuticals (10 articles)
- Treatment Options and Therapeutics for Non-small Cell Lung Cancer in Pharmaceuticals (9 articles)
- Supportive and Palliative Cancer Treatment in Pharmaceuticals (3 articles)